

Temporal Trends in Exposure to Organophosphate Flame Retardants in the United States

Kate Hoffman,[†] Craig M. Butt,[†] Thomas F. Webster,[‡] Emma V. Preston,[‡] Stephanie C. Hammel,[†] Colleen Makey,[‡] Amelia M. Lorenzo,[†] Ellen M. Cooper,[†] Courtney Carignan,[§] John D. Meeker,^{||} Russ Hauser,[§] Adelheid Soubry,[⊥] Susan K. Murphy,^{#,@} Thomas M. Price,[@] Cathrine Hoyo,[∇] Emma Mendelsohn,[†] Johanna Congleton,[●] Julie L. Daniels,[§] and Heather M. Stapleton^{*,†}

[†]Nicholas School of the Environment, Duke University, Durham, North Carolina 27708, United States

[‡]Boston University School of Public Health, Boston, Massachusetts 02118, United States

[§]Harvard T. H. Chan School of Public Health, Boston, Massachusetts 02115, United States

^{||}University of Michigan School of Public Health, Ann Arbor, Michigan 48109, United States

[⊥]Epidemiology Research Group, Department of Public Health and Primary Care, KU Leuven-University, B-3000 Leuven, Belgium

[#]Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina 27710, United States

[@]Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, Duke University Medical Center, Durham, North Carolina 27710, United States


[∇]Department of Biological Sciences, North Carolina State University, Raleigh, North Carolina 27695, United States

[●]Environmental Working Group, Washington, D.C. 20009, United States

[§]Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States

Supporting Information

ABSTRACT: During the past decade, use of organophosphate compounds as flame retardants and plasticizers has increased. Numerous studies investigating biomarkers (i.e., urinary metabolites) demonstrate ubiquitous human exposure and suggest that human exposure may be increasing. To formally assess temporal trends, we combined data from 14 U.S. epidemiologic studies for which our laboratory group previously assessed exposure to two commonly used organophosphate compounds, tris(1,3-dichloro-2-propyl) phosphate (TDCIPP) and triphenyl phosphate (TPHP). Using individual-level data and samples collected between 2002 and 2015, we assessed temporal and seasonal trends in urinary bis(1,3-dichloro-2-propyl) phosphate (BDCIPP) and diphenyl phosphate (DHP), the metabolites of TDCIPP and TPHP, respectively. Data suggest that BDCIPP concentrations have increased dramatically since 2002. Samples collected in 2014 and 2015 had BDCIPP concentrations that were more than 15 times higher than those collected in 2002 and 2003 ($10^{\beta} = 16.5$; 95% confidence interval from 9.64 to 28.3). Our results also demonstrate significant increases in DPHP levels; however, increases were much smaller than for BDCIPP. Additionally, results suggest that exposure varies seasonally, with significantly higher levels of exposure in summer for both TDCIPP and TPHP. Given these increases, more research is needed to determine whether the levels of exposure experienced by the general population are related to adverse health outcomes.



INTRODUCTION

Polybrominated diphenyl ethers (PBDEs) were once among the most widely used flame retardant chemicals applied to consumer products; however, concern over their persistence and toxicity led to their phase-out beginning in the early 2000s. Since then, the chemical flame retardant industry has moved toward replacements.^{1–5} One class of alternatives consists of the organophosphate flame retardants (PFRs), which include chlorinated alkyl phosphates [e.g., tris(1,3-dichloro-2-propyl)

phosphate (TDCIPP)] and nonhalogenated aryl phosphates [e.g., triphenyl phosphate (TPHP)]. Data suggest that PFR use increased after the PBDE phase-out, and they are now among the most commonly detected flame retardants in furniture and

Received: December 27, 2016

Revised: January 26, 2017

Accepted: January 27, 2017

Published: February 8, 2017

Table 1. Characteristics of Included Cohorts and Their Participants in the United States

year of sample collection	state (n)	SG-corrected GM DPHP (ng/mL)	SG-corrected GM BDCIPP (ng/mL)	mean age (standard deviation)	percent male	percent females pregnant	analysis date	analysis method	ref
adults	combined (741)	1.5	1.3	32.3 (9.3)	26.3	48.0			
2002–2005	North Carolina (347) ^a	1.4	1.8	29.6 (5.1)	0.0	100.0	09/2015 10/2015 01/2016	enzyme digestion, SPE, isotope dilution, LC–ESI-MS/MS	17
2002–2007	Massachusetts (45)	0.3	0.1	36.6 (4.3)	100.0	–	11/2011	SPE, isotope dilution, LC–APCI-MS/MS	20
2009	Massachusetts (29)	1.8 ^b	0.4	46.1 (13.9)	17.2	0.0	07/2012	SPE, isotope dilution, LC–APCI-MS/MS	21
2011	North Carolina (9)	3.0	0.4	34.9 (7.4)	44.4	0.0	03/2011	SPE, isotope dilution, LC–APCI-MS/MS	11
2011	Massachusetts (46) ^c	1.7	0.5	39.8 (12.1)	55.3	4.8	01/2014	SPE, isotope dilution, LC–APCI-MS/MS	29
2011–2012	North Carolina (8)	1.9	1.3	– ^d	0.0	100.0	12/2012	SPE, isotope dilution, LC–APCI-MS/MS	18
2011–2012	North Carolina (64)	1.8	0.8	42.6 (12.6) ^e	46.9	0.0	07/2013	SPE, isotope dilution, LC–APCI-MS/MS	19
2012	New Hampshire (11)	7.1	0.7	20.1 (1.1)	0.0	0.0	01/2013	SPE, isotope dilution, LC–APCI-MS/MS	22
2012–2013	North Carolina (69)	1.7	2.3	25.9 (5.1)	100.0	–	03/2014	SPE, isotope dilution, LC–ESI-MS/MS	23
2013–2014	New Jersey (18)	1.9	2.4	39.7 (5.0) ^f	0.0	0.0	03/2014	SPE, isotope dilution, LC–ESI-MS/MS	14
2014–2015	North Carolina (27)	1.7	1.3	22.3 (3.2)	3.7	0.0	04/2014 03/2015	SPE, isotope dilution, LC–ESI-MS/MS	6
2015	California (28)	1.2	3.3	37.2 (3.8)	0.0	0.0	11/2015	enzyme digestion, SPE, isotope dilution, LC–ESI-MS/MS	15
2015	North Carolina (40)	2.4	4.7	29.8 (8.5)	37.5	0.0	09/2015	enzyme digestion, SPE, isotope dilution, LC–ESI-MS/MS	24
children	combined (116)	2.9	6.1	2.8 (2.2)	53.4	–			
2011	Massachusetts (14)	2.0	1.0	6.3 (2.2)	50.0	–	01/2014	SPE, isotope dilution, LC–APCI-MS/MS	29
2013–2014	New Jersey (26)	3.0	5.6	3.2 (0.9) ^g	47.8	–	03/2014	SPE, isotope dilution, LC–ESI-MS/MS	14
2014–2015	North Carolina (43)	3.2	7.3	0.7 (0.4)	63.8	–	04/2015	SPE, isotope dilution, LC–APCI-MS/MS	16
2015	California (33)	2.9	10.9	3.7 (1.5)	53.1	–	11/2015	enzyme digestion, SPE, isotope dilution, LC–ESI-MS/MS	15

^aTwo participants from the original cohort ($n = 349$) who were <18 years of age were excluded from analyses. ^bDPHP data not previously reported and provided by author. ^cOne participant in the original cohort had very dilute urine and was excluded from analyses. ^dIndividual participant ages were not collected and were imputed as 32 years for further statistical analyses. ^eThe participant age was missing for 11 participants and was imputed as a random number within one standard deviation of the cohort mean for further statistical analyses. ^fThe participant age was missing for two participants and was imputed as a random number within one standard deviation of the cohort mean for further statistical analyses. ^gThe participant age and sex were missing for four participants and were imputed as a random number within one standard deviation of the cohort mean for age, or randomly for sex.




Figure 1. Urinary PFR metabolite levels by year. Individual participant values are shown for adults (green) and children (blue). Black dots indicate the geometric mean in each cohort [two geometric means are shown for refs 20 (blue fill), 19 (yellow fill), and 6 (red fill) because samples were collected over two sampling campaigns with different participants].

electronics.^{1–5} Additionally, PFRs are used in other products. For example, TPHP is used as a plasticizer and is found in a variety of applications (e.g., nail polish⁶). Like PBDEs, PFRs are additives that are not chemically bound to products. Consequently, they migrate into indoor air and dust, where they are ubiquitously detected.^{7–10}

In humans, PFRs are thought to be rapidly metabolized and excreted in urine ($t_{1/2}$ of approximately hours). PFR metabolites are used as exposure biomarkers and have been detected in urine samples from people living around the world.^{6,11–27} Although data suggest PFR exposure is widespread and potentially increasing, past studies have been limited in their ability to assess exposure trends because they have generally been conducted over relatively short periods. In addition, comparisons of metabolite concentrations across studies have been limited by differences in cohort composition and potential interlab variability.²⁸ However, by compiling individual-level data from 14 U.S.-based epidemiologic studies conducted by our laboratory in 2002–2015, we are able to more thoroughly evaluate temporal trends in urinary PFR metabolite concentrations. Here, we assess temporal trends in metabolites of TDCIPP and TPHP, bis(1,3-dichloro-2-propyl) phosphate (BDCIPP) and diphenyl phosphate (DPHP), respectively.

MATERIALS AND METHODS

Study Populations. Data were compiled from epidemiologic studies for which our laboratory group previously measured urinary PFR metabolites [857 individuals (Table 1)].^{6,11,14–24,29} Descriptive studies were reported previously and are not discussed in detail here. Briefly, urine samples were collected in 2002–2015 and analyzed in 2009–2016. Individual studies were primarily located in North Carolina or the Northeastern United States, with the exception of one California cohort. Several studies included measurements of the same individuals at multiple time points; however, because measurements were generally closely spaced (i.e., days to weeks apart), we included a single measurement per participant, selected as the first urine sample,^{18,19} or the last for the FLARE study that included only children at the final assessment.²⁹ In addition, two studies were designed to assess contributions of specific exposure sources (fingernail polish and gymnastics practice).^{6,22} From these studies, we selected the measurements intended to represent background exposure. All protocols were

reviewed and approved by the relevant Institution Review Boards.

Urine Analysis. Extraction and analysis procedures for BDCIPP and DPHP have been described previously.^{11,14,15} Briefly, samples were extracted and cleaned with solid-phase extraction (SPE) techniques (Table 1), using identical columns and sorbent material (Strata-X-AW). Some studies included an enzyme digestion step prior to SPE for analysis of BCIPHP sulfate and glucuronide conjugates, but this is not expected to bias DPHP and BDCIPP concentrations because they have no known conjugated metabolites.³⁰ In all studies, deuterium-labeled standards of DPHP and BDCIPP were used for quantification by spiking prior to SPE, and recoveries of internal standards through the extraction process were quantified using ¹³C-labeled DPHP. All samples were analyzed using liquid chromatography and tandem mass spectrometry (LC–MS/MS), although ionization techniques differed between studies, either atmospheric pressure chemical ionization or electrospray ionization. All studies employed thorough QA/QC programs with laboratory blanks and duplicates. Specific gravity was also measured in samples prior to analysis using a digital hand-held refractometer (Atago).

Covariate Data. Although included studies varied in terms of collected covariates, all recorded the date that samples were collected. Individual participant ages were available for 97.1% of participants. If missing, age was imputed as a random number within one standard deviation of the study mean. However, eight women from ref 18 were assigned 32 years of age as they were missing data on age but were known to be pregnant. Sex was available for 99.5% of participants and was randomly imputed for the four participants for which it was missing. Pregnancy status was confirmed for many female participants;^{17,18,29} however, if pregnancy status was not obtained, we assumed they were not pregnant. While the majority of urine samples were spot urines, 40 were first-morning voids and eight were 24 h collections.

Statistical Analysis. Previous publications from each study demonstrate frequent detection of BDCIPP and DPHP. If a particular metabolite was not detected, we imputed the concentration as the method detection limit divided by 2. We visually assessed plots of metabolite concentrations over time (Figure 1) and evaluated the shape of potential relationships using smoothing. On the basis of plot and smoothing results, which suggested that relationships between the date of

Table 2. Regression Analyses with Year (two-year categories) and Season (four categories) of Sample Collection as a Predictor of Urinary PFR Metabolite Levels^a

	no.	BDCIPP		DHPH	
		10 ^β (95% CI)	p value	10 ^β (95% CI)	p value
adults (≥18 years of age)					
2002–2003	132	reference	–	reference	–
2004–2005	248	1.22 (0.98, 1.52)	0.08	1.02 (0.83, 1.26)	0.83
2006–2007	1	–	–	–	–
2008–2009	40	0.81 (0.50, 1.31)	0.39	1.56 (0.99, 2.47)	0.06
2010–2011	67	2.41 (1.57, 3.70)	<0.0001	2.98 (1.99, 4.46)	<0.0001
2012–2013	157	6.86 (4.66, 10.1)	<0.0001	2.94 (2.04, 4.23)	<0.0001
2014–2015	96	16.5 (9.64, 28.3)	<0.0001	1.93 (1.16, 3.20)	0.01
winter	206	reference	–	reference	–
spring	185	2.06 (1.67, 2.53)	<0.0001	0.99 (0.81, 1.20)	0.90
summer	238	4.13 (3.39, 5.04)	<0.0001	1.54 (1.27, 1.85)	<0.0001
fall	112	1.77 (1.38, 2.26)	<0.0001	0.97 (0.77, 1.23)	0.82
children (≤10 years of age)					
2010–2011	14	reference	–	reference	–
2012–2013	25	1.02 (0.28, 3.69)	0.98	0.65 (0.26, 1.60)	0.34
2014–2015	77	3.90 (1.36, 11.1)	0.01	0.74 (0.35, 1.54)	0.41
winter	23	reference	–	reference	–
spring	39	2.28 (0.88, 5.91)	0.09	1.70 (0.87, 3.34)	0.12
summer	32	8.48 (3.16, 22.8)	<0.0001	2.34 (1.16, 4.69)	0.02
fall	22	3.03 (1.32, 6.96)	0.009	0.72 (0.40, 1.29)	0.27

^aExponentiated β coefficients represent the multiplicative change in metabolite concentrations relative to the reference group. Analyses stratified by age and adjusted for sex (male, nonpregnant female, and pregnant female), age (continuous), year of collection, and season of collection.

collection and metabolite levels were nonlinear, collection times were categorized into 2 year periods for analyses. Metabolite concentrations were not normally distributed and were log-transformed in regression analyses. β coefficients from these models were exponentiated for interpretation and represent the multiplicative change in metabolite concentration. Analyses were adjusted for age (continuous), sex (male, nonpregnant female, and pregnant female), and season of collection, factors that previous research suggests may be related to PFR metabolite concentrations.^{12,17,19} We also considered potential confounding by the number of years a sample had been stored prior to analysis; however, storage time (continuous) was strongly collinear with collection date as older samples tended to be stored longer than newer samples before analysis. To address this issue, we dichotomized storage time at 1 year. The dichotomized storage time was not associated with urinary metabolite concentrations and was excluded from the final adjustment set. Although we do not expect the enzyme digestion step or the differing ionization techniques to impact BDCIPP and DPHP levels, we considered potential confounding by the analysis method. The method was not associated with urinary metabolite concentrations and was dropped from analyses. Because previous results suggest that children have greater exposure to PFRs than adults do,^{12,14–16,25} and children were concentrated in later years of sample collection, we conducted analyses separately for children (≤10 years of age) and adults (≥18 years of age). To account for urine dilution, we present results using specific gravity-corrected urine concentrations;³¹ however, uncorrected analyses produced nearly identical results (not shown). Statistical analyses were conducted in SAS version 9.4.

We conducted sensitivity analyses to determine the robustness of results to assumptions about cohort composition, sample type, and analysis. To evaluate the impact of including participants with missing data, we conducted analyses restricted

to participants with complete data. In addition, we conducted analyses including only spot urine samples. Results were indistinguishable from those using all data. Additionally, our final data set contained a number of pregnant women, particularly the 2002–2005 set. To ensure that temporal patterns were not driven by time-dependent differences in the types of participants included (e.g., pregnant women), we conducted secondary analyses excluding pregnant women. Finally, data were collected in several different geographic regions, including California, where exposure may be higher because of stronger flammability standards. We additionally conducted analyses excluding California participants.

RESULTS AND DISCUSSION

Thirteen studies included adults who ranged in age from 18 to 67 years [$n = 741$; mean age of 32.3 ± 9.3 years (Table 1)]. Three of these studies included children, and one additional study focused exclusively on children [$n = 116$; mean age of 2.8 ± 2.2 years (Table 1)]. Among adults, 73.7% of participants were female, and of those, 65.5% were pregnant. Children were more evenly distributed by sex than adults (53.4% male).

BDCIPP and DPHP were detectable in >83% of samples from each study and were detected overall in 96 and 91% of samples, respectively. Individual study participants' metabolite concentrations are shown in Figure 1 along with geometric mean metabolite concentrations for each study. As reported previously, samples from children tended to have metabolite concentrations higher than the concentrations of those from adults, particularly for BDCIPP, a finding highlighted in many studies.^{12,14–16,25} BDCIPP and DPHP levels also tended to be higher among pregnant women, suggesting differences in metabolism and excretion or exposure behavior patterns during pregnancy.

Our results suggest that urinary BDCIPP levels have increased dramatically in recent years (Table 2). Among adults,

samples collected in 2014 and 2015 had BDCIPP concentrations that were 16.5 times those in urine samples collected in 2002 and 2003 [95% confidence interval (CI) from 9.64 to 28.3 (Table 2)]. Although the range of collection dates was narrower, samples from children displayed similar trends; children providing samples in 2014 and 2015 had urinary BDCIPP concentrations that were 3.90 times those in samples collected in 2010 and 2011 [95% CI from 1.36 to 11.1 (Table 2)]. Time trends were similar and slightly stronger when we excluded pregnant women (Table S1). When we excluded California participants, patterns of association remained very similar (Table S2).

Previous research demonstrates that TDCIPP is commonly used in residential furniture and is widely detected in indoor environments; however, there have been few evaluations of temporal trends in different matrices.^{3,8} In a small California house dust assessment, TDCIPP levels were stable between 2006 and 2011.⁹ Interestingly, we saw the largest increases in urinary BDCIPP after this period. Additional data investigating the presence of TDCIPP in residential furniture suggest that use may have increased after the Penta-BDE phase-out but has declined since 2014.³ It will take several more years of data collection to determine if these decreases will impact exposure.

Urinary DPHP concentrations were significantly higher for samples collected in 2010–2015 compared to samples collected in 2002 and 2003. For example, samples collected in 2010 and 2011 had urinary DPHP concentrations 2.98 times those of samples collected in 2002 and 2003 [95% CI from 1.99 to 4.46 (Table 2)]. Although concentrations were also significantly higher in 2014 and 2015, the magnitude of the effect (i.e., OR = 1.93) was smaller than the effect estimates for 2010 and 2011 or 2012 and 2013, suggesting exposure may have peaked during this period and could be in decline. We observed no trends in DPHP concentrations among children; however, children's samples were collected over a period narrower than that of adults (Table 2). Excluding pregnant women and California participants had little impact on results (Tables S1 and S2).

Our results showing increases in DPHP are consistent with a small study showing TPHP increases in household dust between 2006 and 2011.⁹ Although long-term human exposure trends have not been assessed previously, to the best of our knowledge, short-term trends were recently evaluated in pooled samples from Chinese adults.³² Ma et al. reported no change in TPHP concentrations between samples collected in 2011 and 2015 in China, suggesting that exposure levels were relatively constant during this period.³² Our results suggest that TPHP exposure may have started to decrease post-2011, suggesting that TPHP use as a flame retardant or in other applications could be decreasing. Although urinary DPHP is thought to be an indicator of TPHP exposure, other compounds may be metabolized to DPHP and DPHP itself may be used in consumer products.³³

A seasonal trend was observed in urinary BDCIPP; concentrations were significantly higher in spring, summer, and fall than in winter. For example, BDCIPP concentrations were 4.13 times as high in summer as in winter [95% CI from 3.39 to 5.04 (Table 2)]. DPHP concentrations were also higher in summer but to a lesser degree [$10^{\beta} = 1.54$; 95% CI from 1.27 to 1.85 (Table 2)] and were not statistically different in spring and fall versus winter. Cumulatively, these findings suggest that PFR exposure could be temperature-dependent. Indoor temperatures are generally more stable, suggesting that outdoor air or other microenvironments could be more important

drivers of exposure than previously thought. TDCIPP is commonly used in automobiles,³⁴ so it is possible that temperature fluctuations in automobiles (e.g., from sitting in the sun) are driving seasonal exposure differences. Alternatively, seasonal behavior changes could explain patterns (e.g., differences in time spent indoors or changes in ventilation). Regardless of the underlying reason, our results suggest the season of collection could be an important factor to consider in epidemiologic studies relying on single urine samples to assess long-term exposure.

Our results represent the first long-term assessment of human PFR exposure and have the advantage of including numerous measurements conducted by the same laboratory. However, our results should be interpreted in the context of several important limitations. First, data were collected for research of various, unrelated hypotheses; therefore, the study populations included are not representative of the general population. A randomly selected population with longitudinal follow-up would provide a stronger resource for evaluating trends. Several other groups have measured urinary PFR metabolites in different parts of the world.^{12,13,25–27} With the exception of samples from Australia, which had substantially higher DPHP levels,¹² observed concentrations were similar or slightly lower than those analyzed by our group in U.S. studies for the time period under evaluation. We analyzed samples at different points in time with variable storage times and conditions. We did not find associations between concentration and storage times greater than or less than 1 year; however, we were unable to evaluate differences with finer granularity because of collinearity between storage time and collection date. It is possible that samples could degrade over time and potentially impact concentrations; however, this seems unlikely to explain the patterns we observed because we do not see patterns of decrease in analyses with SRM 3673, which we have analyzed numerous times, with variable storage durations. Storage containers were also different across studies; however, it is unlikely that storage method (i.e., glass or plastic) influenced our results, as recent work by Carignan et al. indicates little impact on metabolite concentration.³⁵ Additionally, our analyses primarily relied on spot urine samples. While previous research suggests that spot urine samples are reliable estimates of exposure over time, they are likely subject to greater variation in individual PFR concentrations than first-morning voids or 24 h urine collections because of the rapid metabolism of PFRs.^{18,19} This may explain some of the variability in metabolite concentrations observed. Using individual average urine concentrations rather than spot urine measures would reduce observed scatter in the data. However, we feel that it is unlikely that our use of spot urine samples in this analysis is driving the observed trends. Finally, it is possible that residual confounding may influence the observed differences (e.g., body mass index and behavioral characteristics) but would have to be very strong to explain the entirety of observed trends.

TDCIPP exposure, as indicated by urinary BDCIPP levels, appears to have increased over the past 15 years. Similarly, our data suggest that TPHP exposure also may have increased 2002 to 2011 but may have leveled off or decreased since 2011. Additional data are urgently needed to determine whether levels of exposure experienced by the general population are related to adverse health outcomes.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: [10.1021/acs.estlett.6b00475](https://doi.org/10.1021/acs.estlett.6b00475).

One table that presents results restricted to nonpregnant adults and one table that presents results restricted to participants not living in the state of California at the time of sample collection ([PDF](#))

■ AUTHOR INFORMATION

Corresponding Author

*Nicholas School of the Environment, Duke University, LSRC Box 90328, Durham, NC 27708. E-mail: heather.stapleton@duke.edu. Phone: (919) 613-8717. Fax: (919) 684-8741.

ORCID

Kate Hoffman: [0000-0001-8029-7710](https://orcid.org/0000-0001-8029-7710)

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Portions of this work were funded by the National Institute of Environmental Health Sciences (R01 ES016099 to H.M.S., R21 ES023904 to J.L.D., P01 ES022831 to S.K.M., R01 ES009718 and ES022955 to R.H., T32 ES014562 and R01 ES015829 supporting E.V.P., T32 ES007069 and T32 ES014562 supporting C.C., and R01 ES015829 to T.F.W.), by the U.S. Environmental Protection Agency (RD-83543701 to S.K.M.), and by a Health and the Environment award from the Duke University School of Medicine and the Duke Nicholas School of the Environment to S.K.M. and H.M.S.

■ REFERENCES

- (1) Stapleton, H. M.; Sharma, S.; Getzinger, G.; Ferguson, P. L.; Gabriel, M.; Webster, T. F.; Blum, A. Novel and high volume use flame retardants in US couches reflective of the 2005 PentaBDE phase out. *Environ. Sci. Technol.* **2012**, *46* (24), 13432–13439.
- (2) Stapleton, H. M.; Klosterhaus, S.; Keller, A.; Ferguson, P. L.; van Bergen, S.; Cooper, E.; Webster, T. F.; Blum, A. Identification of Flame Retardants in Polyurethane Foam Collected from Baby Products. *Environ. Sci. Technol.* **2011**, *45* (12), 5323–5331.
- (3) Cooper, E. M.; Kroeger, G.; Davis, K.; Clark, C. R.; Ferguson, P. L.; Stapleton, H. M. Results from Screening Polyurethane Foam Based Consumer Products for Flame Retardant Chemicals: Assessing Impacts on the Change in the Furniture Flammability Standards. *Environ. Sci. Technol.* **2016**, *50* (19), 10653–10660.
- (4) Ballesteros-Gomez, A.; Brandsma, S. H.; de Boer, J.; Leonards, P. E. Analysis of two alternative organophosphorus flame retardants in electronic and plastic consumer products: resorcinol bis-(diphenylphosphate) (PBDPP) and bisphenol A bis (diphenylphosphate) (BPA-BDPP). *Chemosphere* **2014**, *116*, 10–14.
- (5) Kajiwara, N.; Noma, Y.; Takigami, H. Brominated and organophosphate flame retardants in selected consumer products on the Japanese market in 2008. *J. Hazard. Mater.* **2011**, *192* (3), 1250–1259.
- (6) Mendelsohn, E.; Hagopian, A.; Hoffman, K.; Butt, C. M.; Lorenzo, A.; Congleton, J.; Webster, T. F.; Stapleton, H. M. Nail polish as a source of exposure to triphenyl phosphate. *Environ. Int.* **2016**, *86*, 45–51.
- (7) Xu, F.; Giovanoulis, G.; van Waes, S.; Padilla-Sanchez, J. A.; Papadopoulou, E.; Magner, J.; Haug, L. S.; Neels, H.; Covaci, A. Comprehensive Study of Human External Exposure to Organophosphate Flame Retardants via Air, Dust, and Hand Wipes: The Importance of Sampling and Assessment Strategy. *Environ. Sci. Technol.* **2016**, *50* (14), 7752–7760.

- (8) Stapleton, H. M.; Klosterhaus, S.; Eagle, S.; Fuh, J.; Meeker, J. D.; Blum, A.; Webster, T. F. Detection of organophosphate flame retardants in furniture foam and U.S. house dust. *Environ. Sci. Technol.* **2009**, *43* (19), 7490–7495.

- (9) Dodson, R. E.; Perovich, L. J.; Covaci, A.; Van den Eede, N.; Ionas, A. C.; Dirtu, A. C.; Brody, J. G.; Rudel, R. A. After the PBDE phase-out: a broad suite of flame retardants in repeat house dust samples from California. *Environ. Sci. Technol.* **2012**, *46* (24), 13056–13066.

- (10) Wei, G. L.; Li, D. Q.; Zhuo, M. N.; Liao, Y. S.; Xie, Z. Y.; Guo, T. L.; Li, J. J.; Zhang, S. Y.; Liang, Z. Q. Organophosphorus flame retardants and plasticizers: sources, occurrence, toxicity and human exposure. *Environ. Pollut.* **2015**, *196*, 29–46.

- (11) Cooper, E. M.; Covaci, A.; van Nuijs, A. L.; Webster, T. F.; Stapleton, H. M. Analysis of the flame retardant metabolites bis(1,3-dichloro-2-propyl) phosphate (BDCPP) and diphenyl phosphate (DPP) in urine using liquid chromatography-tandem mass spectrometry. *Anal. Bioanal. Chem.* **2011**, *401* (7), 2123–2132.

- (12) Van den Eede, N.; Heffernan, A. L.; Aylward, L. L.; Hobson, P.; Neels, H.; Mueller, J. F.; Covaci, A. Age as a determinant of phosphate flame retardant exposure of the Australian population and identification of novel urinary PFR metabolites. *Environ. Int.* **2015**, *74*, 1–8.

- (13) Su, G.; Letcher, R. J.; Yu, H. Determination of organophosphate diesters in urine samples by a high-sensitivity method based on ultra high pressure liquid chromatography-triple quadrupole-mass spectrometry. *J. Chromatogr. A* **2015**, *1426*, 154–160.

- (14) Butt, C. M.; Congleton, J.; Hoffman, K.; Fang, M.; Stapleton, H. M. Metabolites of organophosphate flame retardants and 2-ethylhexyl tetrabromobenzoate in urine from paired mothers and toddlers. *Environ. Sci. Technol.* **2014**, *48* (17), 10432–10438.

- (15) Butt, C. M.; Hoffman, K.; Chen, A.; Lorenzo, A.; Congleton, J.; Stapleton, H. M. Regional comparison of organophosphate flame retardant (PFR) urinary metabolites and tetrabromobenzoic acid (TBBA) in mother-toddler pairs from California and New Jersey. *Environ. Int.* **2016**, *94*, 627–634.

- (16) Hoffman, K.; Butt, C. M.; Chen, A.; Limkakang, A. T., Jr.; Stapleton, H. M. High Exposure to Organophosphate Flame Retardants in Infants: Associations with Baby Products. *Environ. Sci. Technol.* **2015**, *49* (24), 14554–14559.

- (17) Hoffman, K.; Lorenzo, A.; Butt, C. M.; Adair, L.; Herring, A. H.; Stapleton, H. M.; Daniels, J. L. Predictors of urinary flame retardant concentration among pregnant women. *Environ. Int.* **2017**, *98*, 96–101.

- (18) Hoffman, K.; Daniels, J. L.; Stapleton, H. M. Urinary metabolites of organophosphate flame retardants and their variability in pregnant women. *Environ. Int.* **2014**, *63*, 169–172.

- (19) Hoffman, K.; Garantziotis, S.; Birnbaum, L. S.; Stapleton, H. M. Monitoring indoor exposure to organophosphate flame retardants: hand wipes and house dust. *Environ. Health Perspect.* **2015**, *123* (2), 160–165.

- (20) Meeker, J. D.; Cooper, E. M.; Stapleton, H. M.; Hauser, R. Urinary metabolites of organophosphate flame retardants: temporal variability and correlations with house dust concentrations. *Environ. Health Perspect.* **2013**, *121* (5), 580–585.

- (21) Carignan, C. C.; McClean, M. D.; Cooper, E. M.; Watkins, D. J.; Fraser, A. J.; Heiger-Bernays, W.; Stapleton, H. M.; Webster, T. F. Predictors of tris(1,3-dichloro-2-propyl) phosphate metabolite in the urine of office workers. *Environ. Int.* **2013**, *55*, 56–61.

- (22) Carignan, C.; Fang, M.; Stapleton, H. M.; Heiger-Bernays, W.; McClean, M. D.; Webster, T. F. Urinary biomarkers of flame retardant exposure among collegiate U.S. gymnasts. *Environ. Int.* **2016**, *94*, 362–368.

- (23) Soubry, A.; Butt, C. M.; Fieuws, S.; Hoyo, C.; Price, T. M.; Murphy, S. K.; Stapleton, H. M. Environmental exposure to organophosphates in young men is associated with aberrant DNA methylation at imprinted genes in sperm (manuscript under review).

- (24) Hammel, S. C.; Hoffman, K.; Webster, T. F.; Anderson, K. A.; Stapleton, H. M. Measuring Personal Exposure to Organophosphate

Flame Retardants Using Silicone Wristbands and Hand Wipes. *Environ. Sci. Technol.* **2016**, *50* (8), 4483–4491.

(25) Cequier, E.; Sakhi, A. K.; Marce, R. M.; Becher, G.; Thomsen, C. Human exposure pathways to organophosphate triesters - a biomonitoring study of mother-child pairs. *Environ. Int.* **2015**, *75*, 159–165.

(26) Dodson, R. E.; Van den Eede, N.; Covaci, A.; Perovich, L. J.; Brody, J. G.; Rudel, R. A. Urinary biomonitoring of phosphate flame retardants: levels in California adults and recommendations for future studies. *Environ. Sci. Technol.* **2014**, *48* (23), 13625–13633.

(27) Fromme, H.; Lahrz, T.; Kraft, M.; Fembacher, L.; Mach, C.; Dietrich, S.; Burkardt, R.; Volkel, W.; Göen, T. Organophosphate flame retardants and plasticizers in the air and dust in German daycare centers and human biomonitoring in visiting children (LUPE 3). *Environ. Int.* **2014**, *71*, 158–163.

(28) Melymuk, L.; Goosey, E.; Riddell, N.; Diamond, M. L. Interlaboratory study of novel halogenated flame retardants: INTERFLAB. *Anal. Bioanal. Chem.* **2015**, *407* (22), 6759–6769.

(29) Preston, E. V.; McClean, M. D.; Henn, B. C.; Stapleton, H. M.; Braverman, L. E.; Pearce, E. N.; Makey, C. M.; Webster, T. F. Associations Between Urinary Diphenyl Phosphate and Thyroid Function *Environment International*, in press.

(30) Van den Eede, N.; Maho, W.; Erratico, C.; Neels, H.; Covaci, A. First Insights in the Metabolism of Phosphate Flame Retardants and Plasticizers Using Human Liver Fractions. *Toxicol. Lett.* **2013**, *223* (1), 9–15.

(31) Boeniger, M. F.; Lowry, L. K.; Rosenberg, J. Interpretation of Urine Results Used to Assess Chemical-Exposure with Emphasis on Creatinine Adjustments - a Review. *Am. Ind. Hyg. Assoc. J.* **1993**, *54* (10), 615–627.

(32) Ma, Y.; Jin, J.; Li, P.; Xu, M.; Sun, Y.; Wang, Y.; Yuan, H. Organophosphate ester flame retardant concentrations and distributions in serum from inhabitants of Shandong, China, and changes between 2011 and 2015. *Environ. Toxicol. Chem.* **2017**, *36* (2), 414–421.

(33) Nishimaki-Mogami, T.; Minegishi, K.; Tanaka, A.; Sato, M. Isolation and identification of metabolites of 2-ethylhexyl diphenyl phosphate in rats. *Arch. Toxicol.* **1988**, *61* (4), 259–264.

(34) van der Veen, I.; de Boer, J. Phosphorus flame retardants: properties, production, environmental occurrence, toxicity and analysis. *Chemosphere* **2012**, *88* (10), 1119–1153.

(35) Carignan, C. C.; Butt, C. M.; Stapleton, H. M.; Meeker, J. D.; Mínguez-Alarcón, L.; Williams, P. L.; Hauser, R. Influence of storage vial material on measurement of organophosphate flame retardant metabolites in urine (manuscript under review).